Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$211.17 USD

211.17
2,255,897

-16.27 (-7.15%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix

The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix

    PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y

    PDL BioPharma's (PDLI) earnings surpass expectations. Revenues also significantly increase year over year, thanks to a rise in fair value of the Depomed royalty asset.

      Is a Beat in Store for Ionis (IONS) This Earnings Season?

      Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.

        Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line

        Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.

          Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up

          Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.

            Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed

            Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.

              Biogen (BIIB) Tops Q2 Earnings and Revenue

              Biogen (BIIB) reported better-than expected earnings in the second quarter of 2017 with revenue beating estimates.

                Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

                At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.

                  Mark Vickery headshot

                  Top Stock Reports for Boeing, AbbVie & U.S. Bancorp

                  Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV), and U.S. Bancorp (USB).

                    Arpita Dutt headshot

                    Better Days Ahead for the Pharma Sector?

                    Sales, R&D, strong results, and a higher number of FDA approvals.

                      Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why

                      Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.

                        Kevin Cook headshot

                        Bear of the Day: Bioverativ (BIVV)

                        Biogen spin-off just reported its first quarter and made an acquisition, but estimates were trimmed

                          Biogen Loses Top Executive Again, CFO Clancy to Join Alexion

                          Biogen Inc.'s (BIIB) chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. (ALXN) next month.

                            Biogen/Ionis Spinraza Granted Marketing Authorization in EU

                            Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy.

                              Arpita Dutt headshot

                              5 Drug Stocks in Focus on World MS Day

                              Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.

                                The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture

                                The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture

                                  Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?

                                  On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).

                                    Arpita Dutt headshot

                                    Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug

                                    Key highlights in the biotech sector include a favorable advisory panel vote for Puma (PBYI) and positive data and positive data from companies like Inovio and BioCryst.

                                      Mark Vickery headshot

                                      Top Research Reports for UnitedHealth Group, Union Pacific & Biogen

                                      Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc (UNH), Union Pacific Corporation (UNP) and Biogen Inc (BIIB).

                                        Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer

                                        Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.

                                          Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound?

                                          BIIB reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                            Biogen's Fampyra Conditional Approval Converted to Standard

                                            Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.

                                              Arpita Dutt headshot

                                              Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

                                              Quite a few deals were announced this week including by companies like Biogen (BIIB).

                                                Biogen (BIIB) Buys Stroke Candidate Cirara for $120M

                                                Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).

                                                  The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson

                                                  The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson